STOCK TITAN

eFFECTOR Therapeutics Inc - EFTR STOCK NEWS

Welcome to our dedicated news page for eFFECTOR Therapeutics (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on eFFECTOR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect eFFECTOR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of eFFECTOR Therapeutics's position in the market.

Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced the presentation of new clinical data from a Phase 1/2 study of zotatifin in patients with ER+ metastatic breast cancer at the San Antonio Breast Cancer Symposium 2023. The company plans to discuss the trial results and provide updates on zotatifin development at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
conferences clinical trial
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) reported financial results for Q3 2023 and provided a corporate update. The company is set to provide an update on its zotatifin clinical development program in estrogen receptor-positive metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium. They also anticipate topline results from the Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) in Q1 2024. Additionally, a collaboration with Northwestern University for an investigator-initiated Phase 1 dose escalation trial with tomivosertib in patients with Acute Myeloid Leukemia (AML) has been initiated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference in New York, NY. The Company's CEO will discuss the clinical development pipeline and corporate strategy on November 15 at 12:40 PM ET. A live webcast of the event will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
conferences
Rhea-AI Summary
eFFECTOR Therapeutics has initiated a Phase 1 trial to evaluate tomivosertib in patients with relapsed/refractory Acute Myeloid Leukemia (AML). The trial will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Tomivosertib is an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E (eIF4E).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
-
Rhea-AI Summary
eFFECTOR Therapeutics appoints Caroline Loewy to its Board of Directors and as Chair of the Audit Committee. John Smither resigns from the Board. Loewy's extensive experience brings invaluable insight as the company pushes towards registrational trials and commercialization of its pipeline. With two assets in Phase 2 clinical trials, there is potential for significant value creation and pipeline advancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
management
-
Rhea-AI Summary
eFFECTOR Therapeutics to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.9%
Tags
eFFECTOR Therapeutics Inc

Nasdaq:EFTR

EFTR Rankings

EFTR Stock Data

7.67M
3.38M
3.63%
17.57%
9.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About EFTR

effector therapeutics is a biotechnology company located in 11180 roselle street, san diego, ca, united states.